

Review on Concept of Pharmacovigilance and their Opportunity in India

Rakesh R. Tarare , Rashmi Sonkusare, Chandrashekhar M. Deotale,
Jayesh D. Nil, Piyush G. Ashtankar

New Montfort Institute of Pharmacy, Ashti, Wardha, Maharashtra, India

Abstract: Adverse drug reactions (ADRs) can cause serious health problems, as shown in studies about drug-related hospitalizations. To build knowledge of and raise awareness about ADRs among healthcare professionals, more education in the field of ADRs and pharmacovigilance (PV) is needed. No standard exists for teaching PV at universities for medical, pharmacy, dentistry and nursing students, so a core curriculum needs to be developed to teach important aspects of PV to students. In September 2016, a stakeholders' meeting was initiated on behalf of the World Health Organization (WHO) and organized by the Netherlands

Keywords: Adverse drug reactions

REFERENCES

- [1]. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. *Drug Saf.* 2003;26(12):829–51.
- [2]. World Health Organization. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Geneva: World Health Organization; 2004.
- [3]. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley T, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. *BMJ.* 2004;329(7456):15–9
- [4]. Angamo MT, Chalmers L, Curtain CM, Bereznicki LRE. Adverse drug reaction related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. *Drug Saf.* 2016;39(9):847–57.
- [5]. World health Organisation. The importance of pharmacovigilance—safety monitoring of medicinal products. 2002. [http:// apps.who.int/medicinedocs/en/d/Js4893e/](http://apps.who.int/medicinedocs/en/d/Js4893e/). Accessed 28 Mar 2018
- [6]. Hartman J, Harmark L, van Puijenbroek EP. A global view of undergraduate education in pharmacovigilance. *Eur J Clin Pharmacol.* 2017;7(73):8
- [7]. Arici MA, Gelal A, Demiral Y, Tuncok Y. Short and long-term impact of pharmacovigilance training on the pharmacovigilance knowledge of medical students. *Indian J Pharmacol.* 2015;47(4):436–9.
- [8]. van Grootheest K (2003) The dawn of pharmacovigilance: an historical perspective. *Int J Pharmaceut Med* 17:195. [https://doi.org/ 10.2165/00124363-200317050-00006](https://doi.org/10.2165/00124363-200317050-00006)
- [9]. Schutte T, van Eekeren R, Richir M, van Staveren J, van Puijenbroek E, Tichelaar J, van Agtmael M (2017) The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study. *Naunyn Schmiedeberg's Arch Pharmacol*
- [10]. . Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A (2013) Strategies to improve adverse drug reaction reporting: a critical and systematic review. *Drug Saf* 36(5):317–328
- [11]. . Alessia De Angelis SC, Giusti A, Vellone E, Alvaro R (2015) Factors that condition the spontaneous reporting of adverse drug reactions among nurses: an integrative review. *J Nurs Manag* 24(2)
- [12]. McBride WG. Thalidomide and congenital abnormalities. *Lancet* 1961; 2:1358
- [13]. Available from: <http://www.who-umc.org>. [Last accessed on 2013 Jun 2]
- [14]. World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reactions. Geneva, Switzerland: World Health Organization; 2002

- [15]. . Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. *BMC Clin Pharmacol* 2009;9:14
- [16]. Edwards IR. Who cares about pharmacovigilance? *Eur J Clin Pharmacol* 1997;53:83- 8
- [17]. (WHO, 2002, 2004)
- [18]. Glossary of terms used in pharmacovigilance march 2011.
- [19]. Van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in Reporting adverse drug reactions in an international perspective. *Pharmacoepidemiol Drug Saf.* 2004; 13:457–464.
- [20]. Clause S, Fudin J, Mergner A. Prescribing privileges among pharmacists in Veterans Affairs medical centers. *Am J Health Syst Pharm.* 2001; 58:1143–1145
- [21]. Strom BL, Hennessy S. Pharmacist care and clinical outcomes for patients with reactive airways disease. *JAMA.* 2002; 288:1642–1643.
- [22]. Van Mil F, McElnay J, de Jong-van den Berg LTW, Tromp DFJ. The challenges of defining pharmaceutical care on an international level. *Int J Pharm Pract.* 1999;7:202–208.
- [23]. Beard K. Introduction. In: Strom BL, ed. *Adverse Drug Reactions*. London: Pharmaceutical Press; 2001
- [24]. . Poston J, Parish P. The pharmacist's .In: Inman WHW, ed. *Monitoring for Drug Safety*. Lancaster: MTP Press; 1986.
- [25]. Major E. The yellow card scheme and the role of pharmacists as reporters. *Pharm J.*2002; 269:25–26
- [26]. . Global public policy issues Glaxosmithklines position, pharmacovigilance Jan-2011.
- [27]. *International journal of pharma and bio sciences*vol 2/Issue 1 /Jan 2011
- [28]. Joerg H. *Basic Principles of Pharmacovigilance and Data Sources*.
- [29]. Sachdev Y. *Pharmacovigilance: Safety Matters, Indian Pharmacology*. February 2008;